Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18831779 | 0.83 | ANPEP (0.40) | ANPEPLAP3MEN1KMT2ANPSR1 | |
| SCHEMBL20110437 | 0.79 | MEN1 (0.45) | ANPEPLAP3MEN1KMT2ANPSR1 | |
| SCHEMBL20110445 | 0.79 | MEN1 (0.45) | ANPEPLAP3MEN1KMT2ANPSR1 | |
| SCHEMBL20866551 | 0.77 | BTN3A1 (0.41) | MEN1KMT2ANPSR1BTN3A1ALDH1A1 | |
| SCHEMBL13921741 | 0.76 | MEN1 (0.47) | ANPEPLAP3MEN1KMT2ANPSR1 | |
| SCHEMBL15726977 | 0.76 | BTN3A1 (0.56) | MEN1KMT2ANPSR1BTN3A1ALDH1A1 | |
| SCHEMBL20773105 | 0.74 | ANPEP (0.44) | ANPEPLAP3MEN1KMT2ANPSR1 | |
| SCHEMBL461026 | 0.74 | ANPEP (0.44) | ANPEPLAP3MEN1KMT2ANPSR1 | |
| SCHEMBL4971442 | 0.74 | ANPEP (0.44) | ANPEPLAP3MEN1KMT2ANPSR1 | |
| SCHEMBL9917820 | 0.73 | NPSR1 (0.40) | ANPEPLAP3MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033433-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033433-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | PNP, MTAP, TYMP | ANPEP 200/4885LAP3 502/4885MEN1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.